The role of p53 family tumor suppressors in mediating response to aurora kinase inhibition in triple-negative breast cancer

被引：0
|
作者：
Diamond, J. R. [1 ]
Tan, A. C. [1 ]
Ionkina, A. A. [1 ]
Newton, T. P. [1 ]
Pitts, T. M. [1 ]
Eckhardt, S. G. [1 ]
Tentler, J. J. [1 ]
机构：
[1] Univ Colorado, Ctr Canc, Aurora, CO USA
来源：
CANCER RESEARCH | 2013年 / 73卷
关键词：
D O I：
10.1158/0008-5472.SABCS13-P2-09-06
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P2-09-06
引用
收藏
页数：2
相关论文
共 50 条
  • [21] The expression of MELK, a growth regulator of triple-negative breast cancer, is regulated by p53
    Bollu, Lakshmi Reddy
    Brown, Powel H.
    Mazumdar, Abhijit
    Zhao, Dekuang
    Ma, Yanxia
    CANCER RESEARCH, 2017, 77
  • [22] Differences in prognosis and efficacy of chemotherapy by p53 expression in triple-negative breast cancer
    Soo Youn Bae
    Seok Jin Nam
    Yongsik Jung
    Sae Byul Lee
    Byung-Woo Park
    Woosung Lim
    Sung Hoo Jung
    Hsien Wen Yang
    Seung Pil Jung
    Breast Cancer Research and Treatment, 2018, 172 : 437 - 444
  • [23] Mutant p53: a novel target for the treatment of patients with triple-negative breast cancer?
    Synnott, N. C.
    Murray, A.
    McGowan, P. M.
    Kiely, M.
    Kiely, P. A.
    O'Donovan, N.
    O'Connor, D. P.
    Gallagher, W. M.
    Crown, J.
    Duffy, M. J.
    INTERNATIONAL JOURNAL OF CANCER, 2017, 140 (01) : 234 - 246
  • [24] Therapeutic Role of Tamoxifen for Triple-Negative Breast Cancer: Leveraging the Interaction Between ERβ and Mutant p53
    Scarpetti, Lauren
    Oturkar, Chetan C.
    Juric, Dejan
    Shellock, Maria
    Malvarosa, Giuliana
    Post, Kathryn
    Isakoff, Steven
    Wang, Nancy
    Nahed, Brian
    Oh, Kevin
    Das, Gokul M.
    Bardia, Aditya
    ONCOLOGIST, 2023, : 358 - 363
  • [25] Immunohistochemical status of p53 as prognostic factor in patients with node negative triple-negative breast cancer
    Bae, S. Y.
    Lee, J. E.
    Lee, S. K.
    Nam, S. J.
    ANNALS OF ONCOLOGY, 2016, 27
  • [26] Deregulated MicroRNAs involved in P53 Signaling Pathway in Breast Cancer with Focus on Triple-negative Breast Cancer
    Naeimzadeh, Yasaman
    Heidari, Zahra
    Razban, Vahid
    Khajeh, Sahar
    CURRENT MOLECULAR PHARMACOLOGY, 2024, 17
  • [27] Targeting Mutated p53 Dependency in Triple-Negative Breast Cancer Cells Through CDK7 Inhibition
    Peng, Jingyu
    Yang, Ming
    Bi, Ran
    Wang, Yueyuan
    Wang, Chunxi
    Wei, Xue
    Zhang, Zhihao
    Xie, Xiao
    Wei, Wei
    FRONTIERS IN ONCOLOGY, 2021, 11
  • [28] Differences in prognosis by p53 expression after neoadjuvant chemotherapy in triple-negative breast cancer
    Bae, Soo Youn
    Lee, Jeong Hyeon
    Bae, Jeoung Won
    Jung, Seung Pil
    ANNALS OF SURGICAL TREATMENT AND RESEARCH, 2020, 98 (06) : 291 - 298
  • [29] Modulation of the metastatic propensity of triple-negative breast cancer cells harboring p53 mutations
    Morrsion, B. L.
    Tai, J. W.
    Bernal, F.
    CANCER RESEARCH, 2013, 73
  • [30] Ki-67, p53, and clinical outcomes of patients with triple-negative breast cancer
    Nishiyama, Yasuyuki
    Nishimura, Reiki
    Osako, Tomofumi
    Okumura, Yasuhiro
    Arima, Nobuyuki
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (27)
12345